GlassScriptPhysician profile
Usha Manandhar
NPI 1770079923
$918.28
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $918.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.34 | 2021 | |
| Lilly USA, LLC | $157.03 | 2021 | |
| Esperion Therapeutics, INC. | $146.91 | 2021 | |
| Abbvie INC. | $134.62 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $61.51 | 2021 | |
| Glaxosmithkline, LLC. | $59.45 | 2021 | |
| Astellas Pharma US INC | $54.06 | 2021 | |
| Novo Nordisk INC | $30.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $27.48 | 2021 | |
| Genentech USA, INC. | $21.94 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.70 | 2021 | |
| Bardy Diagnostics, INC. | $14.89 | 2021 | |
| Eisai INC. | $14.23 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usha Manandhar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.